全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Chinese Medicine Shensongyangxin Is Effective for Patients with Bradycardia: Results of a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

DOI: 10.1155/2014/605714

Full-Text   Cite this paper   Add to My Lib

Abstract:

To evaluate the efficacy and safety of Shensong Yangxin (SSYX) in patients with bradycardia arrhythmias, a randomized, double-blind, and placebo-controlled study was conducted. Patients with bradycardia were randomly assigned to receive either SSYX (trial group, ) or placebo (control group, ) for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, and hepatic and renal function were evaluated at baseline and after treatment. Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment ( or 0.01, resp.). Compared with pretreatment, the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group all increased significantly after treatment ( or 0.01, resp.). Both the efficacy and the symptom scores in the trial group were significantly better than those in the control group after treatment (both having ). No severe adverse effects were reported. In conclusion, SSYX treatment significantly increased the heart rate in patients with bradycardia without severe side effects. The exact mechanisms remain to be further explored. 1. Introduction Bradycardia is classified as a pulse rate below 60 beats per minute and is a common phenomenon in both healthy and disease conditions [1, 2]. Bradycardia may be a common manifestation of general conduction system disease or iatrogenic, due to medications used for atrial fibrillation rate control [3], which is characterized by a spectrum of arrhythmias including sinus bradycardia, sinus pauses, atrial fibrillation or flutter, and paroxysmal supraventricular tachycardia. The symptoms of bradyarrhythmia are most commonly intermittent syncope or presyncope but may be general and nonspecific. Some patients with sinus node disease are unable to appropriately increase their heart rate with exercise. Others may present with symptoms due to the underlying cause, such as myocardial infarction or drug toxicity. Bradycardia can include sinus-node dysfunction (sick sinus syndrome) and atrioventricular block [4, 5]. The symptoms are often related to the bradycardia itself, as well as dysfunction of the autonomic nerve system (e.g., dizziness, fatigue, weakness, chest distress, or heart failure). In such cases, treatment targeted solely to correct bradycardia may not be effective in elimination of symptoms [6]. Besides, currently available drugs (e.g., atropine, isoproterenol, and theophylline) used to increase sinus rhythm are not tolerated for long term

References

[1]  R. G. Holly, J. D. Shaffrath, and E. A. Amsterdam, “Electrocardiographic alterations associated with the hearts of athletes,” Sports Medicine, vol. 25, no. 3, pp. 139–148, 1998.
[2]  W. J. Groh, “Arrhythmias in the muscular dystrophies,” Heart Rhythm, vol. 9, no. 11, pp. 1890–1895, 2012.
[3]  L. Feng, J. Gong, Z.-Y. Jin et al., “Electrophysiological effects of Chinese medicine Shen song Yang xin (SSYX) on Chinese miniature swine heart and isolated guinea pig ventricular myocytes,” Chinese Medical Journal, vol. 122, no. 13, pp. 1539–1543, 2009.
[4]  D. Durham and L. I. Worthley, “Cardiac arrhythmias: diagnosis and management. The bradycardias,” Critical Care and Resuscitation, vol. 4, no. 1, pp. 54–60, 2002.
[5]  J. W. Ufberg and J. S. Clark, “Bradydysrhythmias and atrioventricular conduction blocks,” Emergency Medicine Clinics of North America, vol. 24, no. 1, pp. 1–9, 2006.
[6]  W. J. Brady Jr. and R. A. Harrigan, “Diagnosis and management of bradycardia and atrioventricular block associated with acute coronary ischemia,” Emergency Medicine Clinics of North America, vol. 19, no. 2, pp. 371–384, 2001.
[7]  G. Das, “Cardiac effects of atropine in man: an update,” International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 27, no. 10, pp. 473–477, 1989.
[8]  L. Hendeles, M. Weinberger, G. Milavetz, M. Hill III, and L. Vaughan, “Food-induced “dose-dumping” from a once-a-day theophylline product as a cause of theophylline toxicity,” Chest, vol. 87, no. 6, pp. 758–765, 1985.
[9]  D. P. Zipes, A. J. Camm, M. Borggrefe, et al., “ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines,” Journal of the American College of Cardiology, vol. 48, no. 5, pp. e247–e346, 2006.
[10]  W. S. Aronow, “Management of atrial fibrillation in the elderly,” Minerva Medica, vol. 100, no. 1, pp. 3–24, 2009.
[11]  P. Rucinski, A. Rubaj, and A. Kutarski, “Pharmacotherapy changes following pacemaker implantation in patients with bradycardia-tachycardia syndrome,” Expert Opinion on Pharmacotherapy, vol. 7, no. 16, pp. 2203–2213, 2006.
[12]  J. Z. Huang, H. Yan, X.G. Chen, and J. C. Liang, “Effect of Shensong Yangxin Capsule on ventricular premature beat and heart rate variablity,” Modern Medicine and Health, vol. 22, no. 18, pp. 2843–2843, 2006.
[13]  X. X. Shen and W.X. Lu, “Effect of Shensong Yangxin Capsule on sinus node bradycardi,” Chinese Journal of Information on TCM, vol. 15, article 76, 2008.
[14]  N. Li, K.-J. Ma, X.-F. Wu, Q. Sun, Y.-H. Zhang, and J.-L. Pu, “Effects of Chinese herbs on multiple ion channels in isolated ventricular myocytes,” Chinese Medical Journal, vol. 120, no. 12, pp. 1068–1074, 2007.
[15]  S. Chai, S. Wang, L. Yao, A. Wu, Y. Liu, and C. Rao, “Effect of shensongyangxin capsule on myocardial remodeling and ventricular fibrillation threshold value in rat with coronary artery ligation,” Zhongguo Zhongyao Zazhi, vol. 34, no. 16, pp. 2101–2104, 2009.
[16]  N. Li, Y.-P. Huo, K.-J. Ma, Q. Sun, and J.-J. Pu, “Effects of solution of dry powder of ShenSongYangXin capsule on sodium current and L-type calcium current in ventricular myocytes: experiment with guinea pig,” National Medical Journal of China, vol. 87, no. 14, pp. 995–998, 2007.
[17]  K. J. Chen, J. Z. Liao, and Z. X. Xiao, Research on Cardiocerebrovascular Diseases, Shanghai Publishing Company of Science and Technology, Shanghai, China, 1998.
[18]  A.-H. Wang, J.-L. Pu, X.-Y. Qi et al., “Evaluation of shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation: a randomized, double-blind and controlled multicenter trial,” Zhonghua yi Xue Za Zhi, vol. 91, no. 24, pp. 1677–1681, 2011.
[19]  J.-G. Zou, J. Zhang, Z.-H. Jia, and K.-J. Cao, “Evaluation of the traditional chinese medicine shensongyangxin capsule on treating premature ventricular contractions: a randomized, double-blind, controlled multicenter trial,” Chinese Medical Journal, vol. 124, no. 1, pp. 76–83, 2011.
[20]  A. Zheng and T. Moritani, “Effect of the combination of ginseng, oriental bezoar and glycyrrhiza on autonomic nervous activity and immune system under mental arithmetic stress,” Journal of Nutritional Science and Vitaminology, vol. 54, no. 3, pp. 244–249, 2008.
[21]  V. Essebag, T. Hadjis, R. W. Platt, and L. Pilote, “Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction,” Journal of the American College of Cardiology, vol. 41, no. 2, pp. 249–254, 2003.
[22]  L. Shi, X.-C. Yang, X.-L. Liu, M. Zong, and Y.-L. Wu, “Effects of ShenSongYangXin on action potential and some current channels in isolated rabbit pulmonary vein cardiomyocytes,” Zhonghua yi Xue Za Zhi, vol. 89, no. 30, pp. 2142–2146, 2009.

Full-Text

Contact Us

[email protected]

QQ:3279437679

WhatsApp +8615387084133